Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)

NCT01392235 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent Nasopharyngeal Carcinoma
Metastatic Nasopharyngeal Carcinoma

Interventions

DRUG: Famitinib

Sponsor

Jiangsu HengRui Medicine Co., Ltd.

Collaborators

[object Object]